Nkarta (NKTX) Depreciation & Amortization (CF) (2019 - 2026)
Nkarta's quarterly Depreciation & Amortization (CF) came in at $2.3 million in Q1 2026, up 1.78% year-on-year from $2.3 million in Q1 2025, and up 3.68% quarter-over-quarter from $2.3 million in Q4 2025.
Nkarta has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $2.3 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 1.78% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (changed 0.41% YoY), and the FY2025 full-year result was $9.2 million, changed 0.45% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $2.3 million, up from $2.3 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.3 million in Q3 2024, with the low at $610000.0 in Q1 2022.
- Average Depreciation & Amortization (CF) over 5 years is $1.7 million, with a median of $2.3 million recorded in 2024.
- Year-over-year, Depreciation & Amortization (CF) soared 208.78% in 2023 and slipped 1.75% in 2025.
- Tracing NKTX's Depreciation & Amortization (CF) over 5 years: stood at $729000.0 in 2022, then soared by 208.78% to $2.3 million in 2023, then gained by 1.64% to $2.3 million in 2024, then fell by 1.35% to $2.3 million in 2025, then climbed by 3.68% to $2.3 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.34 Mn |
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | 2.26 Mn |
| Dec 31, 2025 | 2.26 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 839,000.00 |
| Jun 30, 2023 | 839,000.00 |
| Mar 31, 2023 | 797,000.00 |
| Mar 31, 2023 | 797,000.00 |
| Dec 31, 2022 | 729,000.00 |
| Dec 31, 2022 | 729,000.00 |
| Sep 30, 2022 | 665,000.00 |
| Sep 30, 2022 | 665,000.00 |
| Jun 30, 2022 | 633,000.00 |
| Jun 30, 2022 | 633,000.00 |
| Mar 31, 2022 | 610,000.00 |
| Mar 31, 2022 | 610,000.00 |
| Dec 31, 2021 | 556,000.00 |
| Dec 31, 2021 | 556,000.00 |
| Sep 30, 2021 | 533,000.00 |
| Sep 30, 2021 | 533,000.00 |
| Jun 30, 2021 | 366,000.00 |
| Jun 30, 2021 | 366,000.00 |
| Mar 31, 2021 | 301,000.00 |
| Mar 31, 2021 | 301,000.00 |
| Dec 31, 2020 | 283,000.00 |
| Dec 31, 2020 | 283,000.00 |
| Sep 30, 2020 | 222,000.00 |
| Sep 30, 2020 | 222,000.00 |
| Jun 30, 2020 | 140,000.00 |
| Jun 30, 2020 | 140,000.00 |
| Mar 31, 2020 | 141,000.00 |
| Mar 31, 2020 | 141,000.00 |
| Dec 31, 2019 | 129,000.00 |
| Dec 31, 2019 | 129,000.00 |
| Sep 30, 2019 | 107,104.00 |
| Sep 30, 2019 | 107,104.00 |